OBJECTIVE: Vasa vasorum are angiogenic in advanced stages of human atherosclerosis and hypercholesterolemic mouse models. Fibroblast growth factor-2 (FGF-2) is the predominant angiogenic growth factor in the adventitia and plaque of hypercholesterolemic low-density lipoprotein receptor-deficient/apolipoprotein B(100/100) mice (DKO). FGF-2 seems to play a role in the formation of a distinct vasa vasorum network. This study examined the vasa vasorum structure and its relationship to FGF-2. METHODS AND RESULTS: DKO mice treated with saline, antiangiogenic recombinant plasminogen activator inhibitor-1(23) (rPAI-1(23)), or soluble FGF receptor 1 were perfused with fluorescein-labeled Lycopersicon esculentum lectin. Confocal images of FGF-2-probed descending aorta adventitia show that angiogenic vasa vasorum form a plexus-like network in saline-treated DKO similar to the FGF-2 pattern of distribution. Mice treated with rPAI-1(23) and soluble FGF receptor 1 lack a plexus; FGF-2 and vasa vasorum density and area are significantly reduced. A perlecan/FGF-2 complex is critical for plexus stability. Excess plasmin produced in rPAI-1(23)-treated DKO mice degrades perlecan and destabilizes the plexus. Plasmin activity and plaque size measured in DKO and DKO/plasminogen activator inhibitor-1(-)(/-) mice demonstrate that elevated plasmin activity contributes to reduced plaque size. CONCLUSIONS: An FGF-2/perlecan complex is required for vasa vasorum plexus stability. Elevated plasmin activity plays a significant inhibitory role in vasa vasorum plexus and plaque development.
OBJECTIVE:Vasa vasorum are angiogenic in advanced stages of humanatherosclerosis and hypercholesterolemicmouse models. Fibroblast growth factor-2 (FGF-2) is the predominant angiogenic growth factor in the adventitia and plaque of hypercholesterolemiclow-density lipoprotein receptor-deficient/apolipoprotein B(100/100) mice (DKO). FGF-2 seems to play a role in the formation of a distinct vasa vasorum network. This study examined the vasa vasorum structure and its relationship to FGF-2. METHODS AND RESULTS: DKO mice treated with saline, antiangiogenic recombinant plasminogen activator inhibitor-1(23) (rPAI-1(23)), or soluble FGF receptor 1 were perfused with fluorescein-labeled Lycopersicon esculentumlectin. Confocal images of FGF-2-probed descending aorta adventitia show that angiogenic vasa vasorum form a plexus-like network in saline-treated DKO similar to the FGF-2 pattern of distribution. Mice treated with rPAI-1(23) and soluble FGF receptor 1 lack a plexus; FGF-2 and vasa vasorum density and area are significantly reduced. A perlecan/FGF-2 complex is critical for plexus stability. Excess plasmin produced in rPAI-1(23)-treated DKO mice degrades perlecan and destabilizes the plexus. Plasmin activity and plaque size measured in DKO and DKO/plasminogen activator inhibitor-1(-)(/-) mice demonstrate that elevated plasmin activity contributes to reduced plaque size. CONCLUSIONS: An FGF-2/perlecan complex is required for vasa vasorum plexus stability. Elevated plasmin activity plays a significant inhibitory role in vasa vasorum plexus and plaque development.
Authors: Mario Gössl; Michael Rosol; Nasser M Malyar; Lorraine A Fitzpatrick; Patricia E Beighley; Mair Zamir; Erik L Ritman Journal: Anat Rec A Discov Mol Cell Evol Biol Date: 2003-06
Authors: Karen S Moulton; Khashayar Vakili; David Zurakowski; Mohsin Soliman; Catherine Butterfield; Erik Sylvin; Kin-Ming Lo; Stephen Gillies; Kashi Javaherian; Judah Folkman Journal: Proc Natl Acad Sci U S A Date: 2003-04-07 Impact factor: 11.205
Authors: Mary Jo Mulligan-Kehoe; Hynda K Kleinman; Mary Drinane; Robert J Wagner; Courtney Wieland; Richard J Powell Journal: J Biol Chem Date: 2002-10-14 Impact factor: 5.157
Authors: Nicolas Baeyens; Mary Jo Mulligan-Kehoe; Federico Corti; David D Simon; Tyler D Ross; John M Rhodes; Thomas Z Wang; Cecile O Mejean; Michael Simons; Jay Humphrey; Martin A Schwartz Journal: Proc Natl Acad Sci U S A Date: 2014-11-17 Impact factor: 11.205
Authors: Daniel G Sedding; Erin C Boyle; Jasper A F Demandt; Judith C Sluimer; Jochen Dutzmann; Axel Haverich; Johann Bauersachs Journal: Front Immunol Date: 2018-04-17 Impact factor: 7.561